GlassScriptPhysician profile
Elizabeth Scheidler
NPI 1467776716
$4,875.91
in general payments reported to CMS, 2019-2025
30 companies · $547 in 2025
The $547 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $859 · 2022: $512 · 2023: $578 · 2024: $2,379 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,197 · Travel and Lodging: $1,223 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,197.34 |
| Travel and Lodging | $1,222.63 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $1,549.69 | 2024 | |
| Abbvie INC. | $707.08 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $452.15 | 2021-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $414.96 | 2021-2025 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $386.39 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Lilly USA, LLC | $148.70 | 2021-2022 | |
| Exact Sciences Corporation | $141.81 | 2023-2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $136.30 | 2025 | Auvelity, Symbravo |
| Astellas Pharma US INC | $126.91 | 2023 | Myrbetriq, Veozah |
| Pfizer INC. | $123.20 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $107.24 | 2025 | Caplyta |
| Amgen INC. | $72.01 | 2021-2024 | Evenity, Prolia |
| Phathom Pharmaceuticals, INC. | $60.28 | 2024 | Voquezna |
| Amarin Pharma, INC. | $56.29 | 2021 | |
| Vanda Pharmaceuticals INC. | $41.66 | 2025 | Fanapt, Hetlioz |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.39 | 2023-2024 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $36.46 | 2021 | |
| Supernus Pharmaceuticals, INC. | $34.39 | 2021 | |
| Kci USA, INC. | $32.86 | 2022-2023 | Promogran Prisma, Adaptic, Activ.A.C. |
| Organon LLC | $31.40 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.72 | 2022 | |
| Paratek Pharmaceuticals, INC. | $21.76 | 2024 | Nuzyra |
| Idorsia Pharmaceuticals US INC | $18.38 | 2022 | |
| Merck Sharp & Dohme LLC | $17.14 | 2022 | |
| Integra Lifesciences Corporation | $17.09 | 2024 | Tcc-Ez |
| Reprise Biomedical, INC. | $16.20 | 2024 | Miro3d |
| Teva Pharmaceuticals USA, INC. | $15.03 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.21 | 2021 | |
| Neurocrine Biosciences, INC. | $13.10 | 2023 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Scheidler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.